Risk of thyroid C-cell tumors with exenatide extended release formulations.
Bydureon is contra-indicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with multiple endocrine neoplasia syndrome Type 2.
- TRADE NAMES: Bydureon (Amylin); Byetta (Amylin)
- INDICATIONS: Type II diabetes mellitus
- CLASS: Antidiabetic, Glucagon-like peptide-1 (GLP-1) receptor agonist, Incretin mimetic, Insulin secretagogue
- HALF-LIFE: 2.4 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Acetaminophen, Alcohol, Antibiotics, Corticosteroids, Lovastatin, Oral Contraceptives, Pegvisomant, Prandial insulin, Somatropin, Sulfonylureas, Thiazide diuretics, Vitamin K antagonists, Warfarin
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 07/15/2024
